BACKGROUND: The aim of this non-interventional study was to evaluate the efficacy and tolerability of propiverine ER under real life conditions. PATIENTS AND METHODS: The treatment of 5,565 patients with urge urinary incontinence, urgency or mixed urinary incontinence was documented over a 12-week period. Incontinence episodes, voiding frequency and voided volume were recorded at 3 visits (admission, after 4 and 12 weeks). Additionally the tolerability was evaluated at visits 2 and 3. RESULTS: The average incontinence episodes/24 h decreased during therapy from 4.23 to 2.89. The frequency of micturitions/24 h decreased by 5.50. The voided volume improved by 69 ml. Approximately 92 % of investigators and patients assessed the efficacy similarly with "very good" and "good". Dry mouth was the most frequent adverse drug reaction and decreased from 16.5 % after 4 weeks to 13.6 % after 12 weeks of treatment. CONCLUSION: The efficacy and tolerability of propiverine ER were confirmed under real life conditions.
BACKGROUND: The aim of this non-interventional study was to evaluate the efficacy and tolerability of propiverine ER under real life conditions. PATIENTS AND METHODS: The treatment of 5,565 patients with urge urinary incontinence, urgency or mixed urinary incontinence was documented over a 12-week period. Incontinence episodes, voiding frequency and voided volume were recorded at 3 visits (admission, after 4 and 12 weeks). Additionally the tolerability was evaluated at visits 2 and 3. RESULTS: The average incontinence episodes/24 h decreased during therapy from 4.23 to 2.89. The frequency of micturitions/24 h decreased by 5.50. The voided volume improved by 69 ml. Approximately 92 % of investigators and patients assessed the efficacy similarly with "very good" and "good". Dry mouth was the most frequent adverse drug reaction and decreased from 16.5 % after 4 weeks to 13.6 % after 12 weeks of treatment. CONCLUSION: The efficacy and tolerability of propiverine ER were confirmed under real life conditions.